COMPANY

Grace Science

HQ: Menlo Park, CA source · gracescience.com ↗ · West Coast

Grace Science is a rare-disease biotech in Menlo Park, CA developing a gene therapy for NGLY1 deficiency, co-founded by CEO Matt Wilsey and Stanford Nobel laureate Carolyn Bertozzi. From press sources Source · Oct 12, 2026

Keywords: gene therapy AAV rare disease NGLY1 deficiency Menlo Park, CA GS-100

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Feb 13, 2024 Trial start Phase 3: Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 3 · Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency · NCT06199531

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06199531	Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency	Phase 3	Active, not recruiting	Feb 13, 2024	2027-03 (estimated)

Connect

Contact page